Skip to content

Study on the role of MDH2 lactylation in tumor microcirculation abnormalities

Study on the role of MDH2 lactylation in tumor microcirculation abnormalities

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125755
Enrollment
Unknown
Registered
2026-05-31
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Liver cancer group:None
colorectal cancer group:None

Sponsors

Suzhou Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18–65 years. 2. Clinically diagnosed with liver cancer, lung cancer, colorectal cancer, or renal cancer, and scheduled to undergo tumor resection. 3. Corresponding tumor confirmed by intraoperative rapid pathology.

Exclusion criteria

Exclusion criteria: Use of preoperative antitumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, anti-angiogenic therapy, etc.

Design outcomes

Primary

MeasureTime frame
Expression of MDH2;

Secondary

MeasureTime frame
Vascular Endothelial Growth Factor (VEGF);Fibroblast Growth Factor-1 (FGF-1);Fibroblast Growth Factor-2 (FGF-2);

Countries

China

Contacts

Public ContactYuqiong Chen

Suzhou Municipal Hospital

cosmoscyq@163.com+86 623 620 2431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026